RecruitingPhase 4NCT07247058
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Studying NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Amir Hamrahian, MDJohns Hopkins University
- Intervention
- Osilodrostat (Isturisa)(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (1)
- Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Collaborators
Recordati Rare Diseases Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07247058 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07361874IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol SecretionUniversity of Texas Southwestern Medical Center
- RECRUITINGPHASE2NCT07104812Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)Mayo Clinic
- ACTIVE NOT RECRUITINGPHASE2NCT06106295Metyrapone for Mild Autonomous Cortisol Secretion (MACS)Mayo Clinic
See all trials for NON RARE IN EUROPE: Cortisol-producing adrenal tumor →